{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:00:35Z","timestamp":1780534835831,"version":"3.54.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Hydroxychloroquine (HCQ) is recommended at a target dose of 5\u2009mg\/kg per actual body weight to reduce the risk of retinopathy in systemic lupus erythematosus (SLE). However, the efficacy of HCQ has been established at doses of 6.5\u2009mg\/kg per ideal body weight. This study aimed to clarify the effects of the HCQ dose on the continuation rate in Japanese patients, who generally have a lower body mass index than Western patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective single-centre observational study enrolled patients with SLE on HCQ therapy. Patients were divided into two groups with a dose per actual body weight [the low-dose (&amp;lt;5\u2009mg\/kg) group and the high-dose (\u22655\u2009mg\/kg) group], and continuation rates were compared. The efficacy of 1-year HCQ therapy was assessed in patients without additional immunosuppressive agents and biologics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 231 patients enrolled, 48 (20.8%) discontinued HCQ. The HCQ dose per actual body weight was identified as an independent risk factor for discontinuation. The low-dose group showed a significantly higher 1-year HCQ continuation rate than the high-dose group (83.2% vs. 72.8%, respectively). Both groups showed reductions in glucocorticoid requirement and serological activity after 1-year HCQ therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HCQ &amp;lt;5\u2009mg\/kg per actual body weight may facilitate greater continuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae062","type":"journal-article","created":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T23:34:29Z","timestamp":1724283269000},"page":"110-117","source":"Crossref","is-referenced-by-count":4,"title":["Relation between hydroxychloroquine dose and continuation rate in patients with systemic lupus erythematosus"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5885-6455","authenticated-orcid":false,"given":"Shuhei","family":"Takeyama","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-534X","authenticated-orcid":false,"given":"Michihito","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniyuki","family":"Aso","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]},{"name":"Department of Internal Medicine, Tomakomai City Hospital , Tomakomai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Kamada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Tarumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Kosumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]},{"name":"Department of General Internal Medicine, Japanese Red Cross Kitami Hospital , Kitami,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Ninagawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]},{"name":"Third Department of Internal Medicine, Obihiro-Kosei Hospital , Obihiro,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Hisada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Fujieda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Amengual","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"2025020515412913100_R1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"2025020515412913100_R2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/0961203314536246","article-title":"Long-term outcome in Japanese patients with lupus nephritis","volume":"23","author":"Kono","year":"2014","journal-title":"Lupus"},{"key":"2025020515412913100_R3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/mr\/roac006","article-title":"Anti-ganglionic nicotinic acetylcholine receptor \u03b13 subunit antibody as a potential biomarker associated with lupus enteritis","volume":"33","author":"Aso","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025020515412913100_R4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/0961203320938453","article-title":"Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus","volume":"29","author":"Aso","year":"2020","journal-title":"Lupus"},{"key":"2025020515412913100_R5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/25785826.2023.2264023","article-title":"A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7\/8 antagonist through academia-industry-government collaboration","volume":"47","author":"Tanaka","year":"2024","journal-title":"Immunol Med"},{"key":"2025020515412913100_R6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/25785826.2023.2202050","article-title":"Association of IL-17 serum levels with clinical findings and systemic lupus erythematosus disease activity index","volume":"46","author":"Ebrahimi Chaharom","year":"2023","journal-title":"Immunol Med"},{"key":"2025020515412913100_R7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/mr\/road090","article-title":"Prevalence, patient characteristics and treatment patterns among SLE-PAH patients in real-world clinical practice: a retrospective analysis of Medical Data Vision Database in Japan","volume":"34","author":"Atsumi","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025020515412913100_R8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R10","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet"},{"key":"2025020515412913100_R11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025020515412913100_R12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R14","first-page":"226","volume-title":"Guideline for the management of systemic lupus erythematosus","author":"Health and Labor Sciences Research Grant Subsidy for Intractable Disease Policy Research","year":"2019","edition":"1st"},{"key":"2025020515412913100_R15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","journal-title":"N Engl J Med"},{"key":"2025020515412913100_R17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025020515412913100_R18","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R19","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025020515412913100_R21","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus"},{"key":"2025020515412913100_R22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/mr\/road014","article-title":"Factors associated with osteoporosis and fractures in patients with systemic lupus erythematosus: Kyoto Lupus Cohort","volume":"34","author":"Nakajima","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025020515412913100_R23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2025020515412913100_R24","first-page":"13","article-title":"Nutrition of the elderly","volume":"5","author":"Katsura","year":"1961","journal-title":"Ronenbyo"},{"key":"2025020515412913100_R25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.10677","article-title":"Risk factors for hydroxychloroquine retinopathy and its subtypes","volume":"7","author":"Jorge","year":"2024","journal-title":"JAMA Network Open"},{"key":"2025020515412913100_R27","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1093\/rheumatology\/keab844","article-title":"Risk of hydroxychloroquine retinopathy in the community","volume":"61","author":"Dabit","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025020515412913100_R28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/ard.51.12.1318","article-title":"Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis","volume":"51","author":"Morand","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/acr.20002","article-title":"Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus","volume":"62","author":"Schmajuk","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025020515412913100_R30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/art.40018","article-title":"Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial","volume":"69","author":"Yokogawa","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025020515412913100_R31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1756-185X.13387","article-title":"Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus","volume":"22","author":"Miyagawa","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2025020515412913100_R32","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2169\/internalmedicine.5042-20","article-title":"Continuation rate, safety and efficacy of hydroxychloroquine treatment in a retrospective cohort of systemic lupus erythematosus in a Japanese Municipal Hospital","volume":"59","author":"Hosokawa","year":"2020","journal-title":"Intern Med"},{"key":"2025020515412913100_R33","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1177\/0961203396005001051","article-title":"Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis","volume":"5","author":"Petri","year":"1996","journal-title":"Lupus"},{"key":"2025020515412913100_R34","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.55563\/clinexprheumatol\/styx9u","article-title":"The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events","volume":"39","author":"Gisondi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025020515412913100_R35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2133.2011.10705.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature","volume":"166","author":"Ziemer","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025020515412913100_R36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"2025020515412913100_R37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy \u2013 implications of research advances for rheumatology care","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025020515412913100_R38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025020515412913100_R39","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000789","article-title":"Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine","volume":"9","author":"Almeida-Brasil","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025020515412913100_R40","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"2025020515412913100_R41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025020515412913100_R42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/acr2.11084","article-title":"Outcomes of systemic lupus erythematosus in patients who discontinue hydroxychloroquine","volume":"1","author":"Aouhab","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2025020515412913100_R43","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02282-0","article-title":"Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study","volume":"22","author":"Fernandez-Ruiz","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025020515412913100_R44","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000395","article-title":"Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus","volume":"7","author":"V\u00e1zquez-Otero","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025020515412913100_R45","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000841","article-title":"Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus","volume":"10","author":"Fasano","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025020515412913100_R46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3899\/jrheum.180946","article-title":"Understanding nonadherence with hydroxychloroquine therapy in systemic lupus erythematosus","volume":"46","author":"Liu","year":"2019","journal-title":"J Rheumatol"},{"key":"2025020515412913100_R47","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00305","article-title":"Frequency of CYP2D6 alleles including structural variants in the United States","volume":"9","author":"Del Tredici","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025020515412913100_R48","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1124\/dmd.108.022368","article-title":"Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans","volume":"37","author":"Lee","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"2025020515412913100_R49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s10038-020-0815-x","article-title":"Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population","volume":"66","author":"Fukunaga","year":"2021","journal-title":"J Hum Genet"},{"key":"2025020515412913100_R50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025020515412913100_R51","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","article-title":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis","volume":"46","author":"Munster","year":"2002","journal-title":"Arthritis Rheum"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae062\/58970855\/roae062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/110\/58970855\/roae062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/110\/58970855\/roae062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:41:53Z","timestamp":1738770113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/1\/110\/7737427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,6]]},"published-print":{"date-parts":[[2024,12,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae062","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,6]]}}}